Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

Are you struggling to unlock the full potential of Process Analytical Technology (PAT) in biomanufacturing?

Look no further!

Join us for a game-changing conversation with Abhijeet Satwekar, an Innovation Manager at Merck Guidonia-Rome, Italy.

Discover how PAT can revolutionize your decision-making, accelerate development timelines, and propel your biotech company to new heights.

Key Learnings:

1. Decoding PAT's Impact: Abhijeet provides unprecedented insights into how PAT technologies revolutionize decision-making in real-time, ensuring unparalleled control over manufacturing processes. Discover the race towards achieving real-time release and initiatives propelling patient-centric value.
2. Fast-Tracking Development Timelines: Explore the potential of PAT in risk reduction by gaining step-by-step insights into process evolution. Uncover how comprehensive data capture can slash Quality Control testing lead times, potentially transforming weeks into mere days.
3. Mastering PAT Implementation Strategies: Abhijeet advocates for simplicity in adopting PAT, commencing with a strategic voice-of-customer approach. Delve into critical process points, select PAT tools judiciously, and establish equivalence with traditional methods for seamless integration.

Get ready to harness the power of PAT and gain a competitive edge in the digital transformation of biomanufacturing.

Don't miss out on this opportunity to become a PAT expert and unlock endless possibilities for success!

Connect with Abhijeet Satwekar:

LinkedIn: https://www.linkedin.com/in/abhijeetsatwekar/

Support the show

Wondering how you can leverage the immense potential of the rapidly evolving world of digital transformation in biomanufacturing?

Join us as we explore the frontiers of technology and innovation with Abhijeet Satwekar, Innovation Manager at Merck Healthcare.

Discover how cutting-edge digital technologies are revolutionizing bioprocesses, optimizing efficiency, and ensuring consistent product quality.

Key Learnings:

1. Process Optimization: Discover the transformative impact of digital technologies on optimizing processes from small-scale studies to large-scale manufacturing, ensuring robustness and consistent product quality.
2. Digital Twin and Efficiency: Explore the realm of digital twins, simulations, and business intelligence tools that revolutionize batch scheduling, planning, and overall bio-manufacturing efficiency.
3. Balancing Innovation and Regulation: Understand the delicate balance between embracing new technologies and satisfying regulatory requirements. Abhijeet provides insights into maintaining confidence through a hybrid model that combines digital insights with traditional process analytical technology.

Tune in for a wealth of knowledge that transcends the boundaries of traditional and digital realms in the quest for groundbreaking biologics.

Connect with Abhijeet Satwekar:

LinkedIn: https://www.linkedin.com/in/abhijeetsatwekar/

Support the show

Welcome back to the second part of our exclusive interview with Steve Oh, former Institute Professor at the Bioprocessing Technology Institute (BTI) at the Agency for Science and Technology (A*STAR) and now Scientific Advisor to several international companies.

In this episode, Steve dives deep into the challenges of manufacturing different cell types, sharing insights gained from his groundbreaking research. From preventing spontaneous differentiation to optimizing multi-stage processes, Steve unveils the complexities of mastering cell therapy development.

Key Takeaways:

• Controlled Differentiation: Learn how Steve tackled the challenge of directed differentiation in a dynamic environment, ensuring cells follow the desired path without spontaneous deviations.
• Scaling Up Strategies: Explore Steve's expertise in choosing the right culture conditions for cultivating various cell types at scale, emphasizing the importance of microcarriers and their impact on maintaining stable states.
• Harvesting and Preservation: Delve into the critical aspects of harvesting cells and preserving their functionality. Discover innovative enzyme-based harvesting methods and the evolving landscape of cryopreservation beyond traditional DMSO.

Join us as Steve shares invaluable insights into the intricate world of cell therapy, offering a roadmap for developers and industry leaders alike. Don't miss this episode packed with expertise and practical advice.

Currently, Steve is an Scientific Advisor to several international companies involved in lentivirus & AAV manufacturing, cryopreservation solutions, biodegradable/edible microcarriers, novel gene delivery methods, cultured meat and stem cell manufacturing.

Connect with Steve Oh:

LinkedIn: https://www.linkedin.com/in/steve-oh-4946261/

Support the show

Dive into the world of cell therapy process development with Steve Oh, former Institute Professor at the Bioprocessing Technology Institute (BTI) at the Agency for Science and Technology (A*STAR) and now Scientific Advisor to several international companies, as he shares thought-provoking perspectives and predictions on technologies that will impact the biotech industry.

In this riveting conversation, Steve Oh unveils secrets to consistent bioproducts and forecasts the future of cell and gene therapy.

Gain a deeper understanding of the evolving landscape and the challenges and opportunities it presents.

Key Takeaways:

1. The Power of Open Mindsets: Discover why carefully orchestrated listening ears lay the foundation for developing solutions in bioprocess development. Learn how avoiding predetermined views enhances the quality of conversations.
2. Beyond Short-Term Goals: Uncover the downside of short-term thinking and how prioritizing long-term improvements can lead to substantial productivity gains. Steve delves into the balance between meeting financial deliverables and achieving lasting advancements.
3. Process Development as a Pillar: Gain insights into why process development is a critical pillar in every biotech company's journey towards scaling. Steve emphasizes the significance of manufacturing consistent biological products and the need to educate scientists on the process's pivotal role.

Join the conversation as Steve Oh unfolds the intricate world of cell therapy process development, offering a roadmap from lab exploration to patient impact.

Currently, Steve is an Scientific Advisor to several international companies involved in lentivirus & AAV manufacturing, cryopreservation solutions, biodegradable/edible microcarriers, novel gene delivery methods, cultured meat and stem cell manufacturing.

Connect with Steve Oh:

LinkedIn: https://www.linkedin.com/in/steve-oh-4946261/

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

Unlock the secrets of cell-line development with Tanner Nevill, the SVP of Applications at Bruker Cellular Analysis and one of the primary inventors and developers of the Beacon Optofluidic Platform.

In this interview, Tanner delves into the transformative power of nanopens and microenvironments in cell-line development.

Key Takeaways:

1. Nanopens Redefining Norms: Tanner introduces the game-changing nanopens, disrupting traditional cell line development. Learn how these innovative tools are reshaping the landscape and ushering in a new era of efficiency.
2. AI's Impact on In Silico Discovery: Explore the future of cell-line development as Tanner discusses the integration of AI. Uncover how in silico discovery and engineering are poised to revolutionize processes, prompting a shift towards early functional testing and accelerated throughput.
3. Strategies for Small Players: Gain insights into practical strategies for smaller companies seeking to enhance throughput and reduce cell-line development durations. Tanner emphasizes the importance of understanding cost dynamics and leveraging data-driven decision-making.

Join us as Tanner Nevill navigates the dynamic intersection of technology and life sciences, offering a glimpse into the evolving landscape of cell-line development.

Connect with Tanner Nevill:

For more on Tanner's insights and the revolutionary Beacon Optofluidic Platform, connect with him on LinkedIn or search for "beacon, CLD or CLD beacon."

LinkedIn: www.linkedin.com/in/tannernevill

Website: https://brukercellularanalysis.com/products/workflows/cell-line-development

Support the show

In this episode, Tanner Nevill, the SVP of Applications at Bruker Cellular Analysis and one of the primary inventors and developers of the Beacon Optofluidic Platform, shares insights into revolutionizing cell-line development through nanopens and microenvironments.

Key Takeaways:

1. Challenging the Status Quo: Tanner challenges conventional thinking, highlighting the limitations of planar cell cultures and the shortcomings of traditional approaches in the field. His perspective sparks a conversation about the need for innovative thinking in bioprocess development.
2. The Multidisciplinary Nature of Cell-Line Development: Tanner emphasizes the importance of multidisciplinary collaboration in the industry. He stresses that success in bioprocess development requires not only scientific expertise but also effective communication and teamwork across diverse disciplines.
3. Critical Aspects for High Productivity Clones: The discussion explores the significance of microenvironments in cell-line development. Tanner introduces the concept of nanopens—tiny chambers that mimic bioreactor conditions, enabling precise screening and optimization for high productivity clones.

Join us as we uncover the dynamic intersection of science and engineering, challenging the norms in cell-line development.

Connect with Tanner Nevill:

LinkedIn: www.linkedin.com/in/tannernevill

Website: https://brukercellularanalysis.com/products/workflows/cell-line-development

Support the show

In the second part of our insightful interview with Payar Radfar, CEO of Smart MCs, we delve into the practical steps of developing adherence cell cultures for bioprocessing scalability.

Payar emphasizes the critical need for patience and a methodical approach, recounting how many clients rush into large-scale cultures prematurely. The key takeaways include:

1. Start Small, Stay Patient: Begin with small cultures and test various microcarriers. Patience is crucial; rushing can lead to ambiguous results and hinder long-term success.

2. Role of Modeling: Payar discusses the potential of AI modeling in scaling up processes. While AI can save time, he emphasizes the importance of a cautious, step-by-step approach.

3. Avoid Pitfalls: Highlighting the diverse nature of cell types, microcarriers, and bioreactors, Payar warns against assuming uniformity. Each component plays a crucial role, requiring careful consideration and gradual adjustments.

Join us as we explore future trends in bioprocessing, where Payar anticipates breakthroughs in media formulation and the use of novel technologies like microfluidics. Discover the broad applications beyond cellular therapies and cultivated meat, reaching into vaccine production and other cell-dependent fields.

Tune in now to gain invaluable insights into the dynamic world of adherence cell cultures and the promising future of bioprocessing innovation.

Connect with Payar Radfar:

Website: https://smartmcs.com.au/

LinkedIn: linkedin.com/company/smart-mcs

Twitter: twitter.com/SmartMCsPTYLTD

Support the show

In this episode, we explore the world of adherent cell cultures with Payar Radfar, CEO of Smart MCs. Smart MCs specializes in customized biomaterials and microfluidic solutions. Payar shares his unique journey in the biotech industry, driven by his passion for improving people's health.

Key Takeaways:

1. Revolutionizing Bioprocessing: Payar discusses the challenges scientists face when transitioning from lab-scale to industrial-scale production. He emphasizes the importance of a multidisciplinary approach and envisions his company playing a crucial role in simplifying and enhancing bioprocessing technologies.

2. Cost Challenges in Cellular Therapies: Payar addresses the high costs associated with cellular therapies and explores the barriers to wider distribution. He highlights the role of competition and regulations in reducing costs and increasing accessibility to these therapies.

3. The Power of Microcarriers: The technical discussion focuses on microcarriers and their vital role in adherent cell cultures. Payar explains how these microscopic spheres enable efficient scaling up of cell production in bioreactors, offering a glimpse into the future of bioprocessing.

Are you curious about the transformative potential of microcarriers and the future of bioprocessing?

Join us in this insightful conversation with Payar Radfar as we uncover the secrets behind scaling up adherent cell cultures and their profound impact on the biotech industry.

Connect with Payar Radfar:

Website: https://smartmcs.com.au/

LinkedIn: linkedin.com/company/smart-mcs

Twitter: twitter.com/SmartMCsPTYLTD

Support the show

In the second part of our conversation with Michael Sokolov, the co-founder and COO of DataHow, we dive into practical insights on leveraging hybrid modeling in bioprocessing.

You will discover:

1. Starting Small, Dreaming Big: Even in smaller companies, you can start with a minimal number of reactors and still leverage hybrid modeling effectively. Whether it's just a few shakers or a handful of bioreactors, you can begin the journey to process improvement.

2. The Power of Digital Twins: Michael sheds light on the concept of digital twins, which involves creating a real-time model of your bioprocess. It not only helps optimize the process but also enables feedback control, reducing manual operations and adapting to changes on the fly.

3. Regulatory Acceptance: While the pharmaceutical industry is known for its conservatism, regulators are becoming more receptive to innovative technologies like hybrid modeling. Health authorities are encouraging the use of promising tools in process development and are not imposing specific technologies. As more companies adopt these tools and gather data on their effectiveness, they are likely to play a more prominent role in regulatory filings.

Don't miss out on this insightful discussion with Michael Sokolov as he unravels the potential of hybrid modeling in bioprocessing. If you're looking to simplify and streamline your bioprocessing journey, this episode is a must-listen.

Connect with Michael Sokolov:

Website: www.datahow.ch

Support the show

In this insightful conversation, we explore how to accelerate bioprocess development and enhance manufacturing using hybrid modeling. Our guest, Michael Sokolov, COO of DataHow (a spin-off company from ETH Zurich), shares valuable insights.

Discover the three major takeaways that could transform the bioprocessing industry:

1. Unlocking the Power of Hybrid Modeling: Michael Sokolov introduces the revolutionary concept of hybrid modeling, which combines mechanistic knowledge with machine learning to expedite bioprocess development.

2. Accelerating Process Development: Learn how hybrid modeling can speed up your bioprocessing efforts, potentially allowing you to reduce the number of experiments by 60-80%, saving valuable time and resources.

3. Data-Driven Decision Making: Gain insights into how this approach enables data-driven decision making in the unpredictable world of biotech. It provides a deep understanding and empowers scientists to make informed choices.

Don't miss this episode for a comprehensive guide to smarter and more efficient bioprocessing!

Connect with Michael Sokolov:

Website: www.datahow.ch

Support the show